This article first appeared on GuruFocus .
-
GAAP Net Loss:$33.4 million for Q4 2025, compared to $14.1 million in Q4 2024.
-
Revenue:$3.7 million for the reported period, up from $3.0 million in the comparable period.
-
Gross Loss:$3.6 million on a GAAP basis for the quarter, compared to $2.9 million in the comparable period.
-
Non-GAAP Gross Loss:$1.2 million for the reported period, compared to $0.3 million in the comparable period.
-
Teleradiology Services Revenue:$3.1 million for the reported period, up from $2.8 million in the comparable period.
-
Teleradiology Services Gross Profit:$0.9 million with a gross profit margin of approximately 27% for the reported period.
-
AI and Software Solutions Revenue:$0.5 million for the reported period, compared to $0.1 million in the comparable period.
-
Research and Development Expenses:$4.8 million for the reported period, down from $5.4 million in the comparable period.
-
Sales and Marketing Expenses:$2.0 million for the reported period, up from $0.9 million in the comparable period.
-
General and Administrative Expenses:$6.0 million for the reported period, compared to $5.8 million in the comparable period.
-
Cash, Cash Equivalents, and Marketable Securities:Approximately $60 million as of December 31, 2025.
-
Shares Outstanding:Approximately 69.6 million as of December 31, 2025.
Release Date: April 20, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Nano X Imaging Ltd ( NASDAQ:NNOX ) entered into a significant agreement with Howard Technology Solutions to deploy 300 Nanox.ARC systems over three years, indicating strong commercial demand.
-
The company announced multiple commercial agreements, totaling approximately 360 systems over two to three years, expanding their reach across imaging centers and specialty care settings.
-
Nano X Imaging Ltd ( NASDAQ:NNOX ) is targeting $35 million in revenue for the full year of 2026, based on current plans and agreements.
-
The company is restructuring its Korean manufacturing facility to reduce operational expenses and improve efficiency, aligning with long-term financial goals.
-
Nano X Imaging Ltd ( NASDAQ:NNOX ) received international recognition, including the Red Dot Award for product design and the newcomer award at the European Congress of Radiology, reflecting growing market recognition.
Negative Points
-
The company reported a GAAP net loss of $33.4 million for the fourth quarter of 2025, significantly higher than the $14.1 million loss in the same period of 2024.
-
Revenue for the reported period was only $3.7 million, indicating slow growth and early-stage revenue generation.
-
The pace of system deployment is influenced by external factors such as import licenses, construction timelines, and regulatory requirements, causing delays.
-
The restructuring plan includes a non-cash impairment of $17.5 million related to the Korean manufacturing facility, impacting financial results.
-
Despite commercial progress, the company acknowledges that part of the deployed base is not yet generating revenue, with future revenue dependent on system activation and utilization.
Q & A Highlights
Q: Could you talk about your footprint and commercial organization in the U.S., particularly regarding direct sales teams and distribution channels? A: We have five direct salespeople in the U.S., led by a national sales director from a major distributor. We also have clinical education specialists to train and build awareness at installation sites. Additionally, we are adding two more people for channel management to coordinate with our ten business partners.
Q: Regarding the South Korean facility and the impairment, what should we expect for 2026? Will there be further restructuring and impairment, and will it be cash or non-cash? A: Besides the $17.5 million non-cash impairment recorded in 2025, we anticipate minor cash expenses related to efficiency improvements. The South Korean facility will transition to an R&D center, focusing on ceramic teams and potentially new products.
Q: For the 2026 guidance of $35 million, when will we see the inflection point to reach these numbers? A: Most revenue growth is expected in the second half of 2026. Many agreements were signed recently, and we are in the onboarding process, with a ramp-up anticipated towards the latter part of the year.
Q: For teleradiology services, should we expect low double-digit growth for 2026? A: While we haven't provided specific guidance for segments, your assumption of low double-digit growth is reasonable.
Q: How should we think about spending trends going forward, considering the elevated Q4 levels due to restructuring? A: The increase in Q4 was due to seasonal G&A expenses and one-time acquisition costs. Sales and marketing expenses related to U.S. commercialization efforts may continue, but participation in events like RSNA will depend on future decisions.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
